All lobbying filings

RICCHETTI INCORPORATED

RICCHETTI INCORPORATED filed a Q1 report for IPSEN BIOPHARMACEUTICALS, INC. on April 16, 2025, reporting $20,000 in lobbying income.

Lobbying for IPSEN BIOPHARMACEUTICALS, INC. · Biopharmaceutical company

All filings by RICCHETTI INCORPORATED · Everything IPSEN BIOPHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 16, 2025

Income

$20,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)

Medicare/Medicaid

Issues related to coverage of diagnostic testing for cancer; H.R.842/S.339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Bills named in this filing 2

H.R. 842
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
S. 339
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.